Advanced Filters
noise

nonalcoholic-steatohepatitis Clinical Trials

A listing of nonalcoholic-steatohepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 156 clinical trials
D Dalia Perelman

Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance

This 12-week controlled diet and weight intervention study seeks to define the molecular pathways that link excess body weight to the development of insulin resistance (IR). Blood, adipose and stool are sampled at three timepoints; baseline, peak weight (4 weeks) and post weight loss to monitor changes in cellular processes. …

35 - 65 years of age All Phase N/A
D Dr Prakash K. Sasmal, MS, FACS

Comorbidities Resolution After MGB Surgery and Change in Body Composition

This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are: To study the correlation between the improving comorbidities associated with obesity after …

18 - 65 years of age All Phase N/A
L Leen Heyens, MsC

Prevalence of NAFLD in T1DM Patients

To determine the prevalence of NAFLD in T1DM patients.

18 years of age All Phase N/A
C Chiu Wing CHU, MBChB, MD

Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention

The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery. To test the hypothesis that Brown fat is an independent biomarker for the development of Non Alcoholic Fat Liver Disease (NAFLD) To study the association among …

18 - 65 years of age All Phase N/A

The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes

The primary aim of this randomized cross-over intervention study is to investigate the effect of four weeks of intermittent carbohydrate restriction (alternating between two days of normal dietary intake and two days of carbohydrate restriction to 70-90 grams) on 24-hour average sensor glucose in individuals with type 2 diabetes compared …

35 - 75 years of age All Phase N/A
Z Zhen J Peng, Phd

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat …

18 - 75 years of age All Phase 2
A Adam T Whaley-Connell, DO MSPH

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in the military and Veteran population compared to the general US population. NASH may progress to end-stage liver disease and primary liver cancer, and hence …

18 - 75 years of age All Phase 2
Y Yaira Mathison

Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)

The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis. The main question it aims to answer is: \- To determine if the treatment with NAM is able to arrest, or even reduce, the hepatic fibrosis. In addition, …

18 - 85 years of age All Phase 2
M Michele B. Ryan, MS

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of …

18 years of age All Phase N/A
K Kenneth Cusi, M.D.

Low-Dose Pioglitazone in Patients With NASH (AIM 2)

To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

21 - 75 years of age All Phase 2

Simplify language using AI